XMRV and prostate cancerg - A 'final' perspective

Karen S. Sfanos; Amanda L. Aloia; Angelo M. De Marzo; Alan Rein

doi:10.1038/nrurol.2011.225

XMRV and prostate cancerg - A 'final' perspective

Karen S. Sfanos, Amanda L. Aloia, Angelo M. De Marzo, Alan Rein

Research output: Contribution to journal › Review article › peer-review

16 Scopus citations

Abstract

XMRV was first described in 2006, when it was identified in samples isolated from prostate cancer tissues. However, studies have since shown that XMRV arose in the laboratory and was formed by genetic recombination between two viral genomes carried in the germline DNA of mice used during serial transplantation of the CWR22 prostate cancer xenograft. These new findings strongly imply that XMRV does not circulate in humans, but is only present in the laboratory. Thus, there is no reason to believe that it has any role in the etiology of prostate cancer or other diseases.

Original language	English (US)
Pages (from-to)	111-118
Number of pages	8
Journal	Nature Reviews Urology
Volume	9
Issue number	2
DOIs	https://doi.org/10.1038/nrurol.2011.225
State	Published - Feb 2012

ASJC Scopus subject areas

Urology

Access to Document

10.1038/nrurol.2011.225

Cite this

@article{adf0caaf9b464b8485c53a774998dfd9,

title = "XMRV and prostate cancerg - A 'final' perspective",

abstract = "XMRV was first described in 2006, when it was identified in samples isolated from prostate cancer tissues. However, studies have since shown that XMRV arose in the laboratory and was formed by genetic recombination between two viral genomes carried in the germline DNA of mice used during serial transplantation of the CWR22 prostate cancer xenograft. These new findings strongly imply that XMRV does not circulate in humans, but is only present in the laboratory. Thus, there is no reason to believe that it has any role in the etiology of prostate cancer or other diseases.",

author = "Sfanos, {Karen S.} and Aloia, {Amanda L.} and {De Marzo}, {Angelo M.} and Alan Rein",

note = "Funding Information: The authors would like to acknowledge Dr Saraswati Sukumar for helpful discussions. Research by A. Aloia and A. Rein is supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.",

year = "2012",

month = feb,

doi = "10.1038/nrurol.2011.225",

language = "English (US)",

volume = "9",

pages = "111--118",

journal = "Nature Reviews Urology",

issn = "1759-4812",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - XMRV and prostate cancerg - A 'final' perspective

AU - Sfanos, Karen S.

AU - Aloia, Amanda L.

AU - De Marzo, Angelo M.

AU - Rein, Alan

N1 - Funding Information: The authors would like to acknowledge Dr Saraswati Sukumar for helpful discussions. Research by A. Aloia and A. Rein is supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.

PY - 2012/2

Y1 - 2012/2

N2 - XMRV was first described in 2006, when it was identified in samples isolated from prostate cancer tissues. However, studies have since shown that XMRV arose in the laboratory and was formed by genetic recombination between two viral genomes carried in the germline DNA of mice used during serial transplantation of the CWR22 prostate cancer xenograft. These new findings strongly imply that XMRV does not circulate in humans, but is only present in the laboratory. Thus, there is no reason to believe that it has any role in the etiology of prostate cancer or other diseases.

AB - XMRV was first described in 2006, when it was identified in samples isolated from prostate cancer tissues. However, studies have since shown that XMRV arose in the laboratory and was formed by genetic recombination between two viral genomes carried in the germline DNA of mice used during serial transplantation of the CWR22 prostate cancer xenograft. These new findings strongly imply that XMRV does not circulate in humans, but is only present in the laboratory. Thus, there is no reason to believe that it has any role in the etiology of prostate cancer or other diseases.

UR - http://www.scopus.com/inward/record.url?scp=84857035507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857035507&partnerID=8YFLogxK

U2 - 10.1038/nrurol.2011.225

DO - 10.1038/nrurol.2011.225

M3 - Review article

C2 - 22231291

AN - SCOPUS:84857035507

SN - 1759-4812

VL - 9

SP - 111

EP - 118

JO - Nature Reviews Urology

JF - Nature Reviews Urology

IS - 2

ER -

XMRV and prostate cancerg - A 'final' perspective

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this